Loading Calculator...
Please wait a moment
Please wait a moment
Calculate the Urticaria Activity Score over 7 days (UAS7) to assess chronic urticaria severity and guide treatment decisions.
Instructions: Record daily wheals and itch severity for 7 consecutive days. Rate symptoms at the worst point each day, preferably at the same time each evening.
The Urticaria Activity Score over 7 days (UAS7) is a validated patient-reported outcome measure for assessing chronic spontaneous urticaria (CSU) severity. It captures both the physical manifestation (wheals) and the subjective symptom (itch) over a full week.
UAS7 is the sum of all daily scores over 7 consecutive days, ranging from 0 (no disease) to 42 (maximum disease). The score helps clinicians assess disease activity, monitor treatment response, and make informed decisions about treatment adjustments.
The primary treatment goal for chronic urticaria is achieving UAS7 ≤ 6, indicating complete or well-controlled disease. Clinical trials often use UAS7 = 0 (complete control) or minimal UAS7 scores as endpoints for evaluating treatment efficacy.
Chronic spontaneous urticaria (CSU) is defined as the occurrence of wheals (hives), angioedema, or both, for more than 6 weeks without an identifiable external trigger. UAS7 is specifically designed to monitor disease activity in CSU.
UAS is the daily score (maximum 6 per day: wheals 0-3 + itch 0-3), while UAS7 is the sum of UAS scores over 7 consecutive days (maximum 42). UAS7 provides a more comprehensive assessment of disease activity over time.
Count the number of new wheals that appear during each 24-hour period. If wheals are very numerous or form large confluent areas covering significant body surface area, this automatically scores as 3 regardless of exact count.
Record your worst symptoms during each 24-hour period. It's normal for urticaria symptoms to fluctuate throughout the day. The UAS7 captures peak symptom severity to reflect overall disease burden.
UAS7 should be calculated at baseline before starting treatment and repeated during follow-up to monitor treatment response. Typical assessment intervals are every 4-12 weeks depending on treatment changes and disease stability.
A UAS7 score of ≤6 indicates well-controlled or complete disease control and is the treatment goal. Many clinical trials also look for percentage improvement from baseline, with 75% reduction considered a good response.
UAS7 is specifically validated for chronic spontaneous urticaria. For physical urticarias (triggered by specific stimuli like cold, pressure, or sun), other assessment tools that capture trigger-induced symptoms may be more appropriate.
Yes, continue all prescribed medications as directed. UAS7 is used to assess disease control on your current treatment regimen. Changes in UAS7 help guide decisions about treatment adjustments or intensification.
Assess eczema severity using SCORAD index
Calculate body surface area for psoriasis
Calculate Psoriasis Area and Severity Index
Assess food allergy risk in infants
Evaluate medication allergy cross-reactivity
Screen for depression severity